EA-230 is under clinical development by Exponential Biotherapies and currently in Phase II for Acute Inflammation.

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

The association between psoriasis severity and CVD may be mediated by systemic inflammation, with a statistically significant ...

Objective—To determine the presence or absence of an acute phase response after training for court and field sports. Participants—All members of the Australian women's soccer team (n = 18) and all ...

The energy-storing Achilles shares common cellular and molecular inflammatory mechanisms with functionally distinct rotator cuff positional tendons. Differences seen in the profile of ruptured ...

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

Orticumab is under development for the treatment of acute coronary syndrome and coronary inflammation. The drug candidate is administered intravenously. It is developed based on F.I.R.S.T Technology.

NLRP3 inflammasome activation, pro-inflammatory cytokine production and pyroptosis are key features of inflammation that contribute to liver fibrosis progression, cirrhosis and end-stage liver failure ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.